RU2595801C2 - Фармацевтическая композиция для лечения заболеваний сердца - Google Patents
Фармацевтическая композиция для лечения заболеваний сердца Download PDFInfo
- Publication number
- RU2595801C2 RU2595801C2 RU2011145370/15A RU2011145370A RU2595801C2 RU 2595801 C2 RU2595801 C2 RU 2595801C2 RU 2011145370/15 A RU2011145370/15 A RU 2011145370/15A RU 2011145370 A RU2011145370 A RU 2011145370A RU 2595801 C2 RU2595801 C2 RU 2595801C2
- Authority
- RU
- Russia
- Prior art keywords
- cells
- pharmaceutical composition
- group
- fgf
- committed
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 78
- 208000019622 heart disease Diseases 0.000 title claims abstract description 10
- 210000005003 heart tissue Anatomy 0.000 claims abstract description 32
- 239000000126 substance Substances 0.000 claims abstract description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 17
- 239000003755 preservative agent Substances 0.000 claims abstract description 16
- 230000002335 preservative effect Effects 0.000 claims abstract description 16
- 206010019280 Heart failures Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000000302 ischemic effect Effects 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 150000002500 ions Chemical class 0.000 claims abstract description 9
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 8
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims abstract description 7
- 208000035475 disorder Diseases 0.000 claims abstract description 7
- 239000002207 metabolite Substances 0.000 claims abstract description 7
- 208000014471 histiocytoid cardiomyopathy Diseases 0.000 claims abstract description 6
- 230000001684 chronic effect Effects 0.000 claims abstract description 5
- 206010000891 acute myocardial infarction Diseases 0.000 claims abstract description 4
- 239000000084 colloidal system Substances 0.000 claims abstract description 4
- 230000000149 penetrating effect Effects 0.000 claims abstract description 4
- 239000006174 pH buffer Substances 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 192
- 238000000034 method Methods 0.000 claims description 54
- 210000000130 stem cell Anatomy 0.000 claims description 36
- 230000015572 biosynthetic process Effects 0.000 claims description 30
- 230000001269 cardiogenic effect Effects 0.000 claims description 26
- 241000282414 Homo sapiens Species 0.000 claims description 20
- 108010018650 MEF2 Transcription Factors Proteins 0.000 claims description 18
- 102100039229 Myocyte-specific enhancer factor 2C Human genes 0.000 claims description 18
- 101150114527 Nkx2-5 gene Proteins 0.000 claims description 18
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- -1 Mesp1 Proteins 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 15
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 14
- 238000004458 analytical method Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 101150115978 tbx5 gene Proteins 0.000 claims description 13
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 12
- 210000001185 bone marrow Anatomy 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 claims description 11
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 claims description 11
- 101000931374 Homo sapiens Zinc finger protein ZFPM1 Proteins 0.000 claims description 11
- 101000931371 Homo sapiens Zinc finger protein ZFPM2 Proteins 0.000 claims description 11
- 101150088608 Kdr gene Proteins 0.000 claims description 11
- 102100021380 Transcription factor GATA-4 Human genes 0.000 claims description 11
- 102100021382 Transcription factor GATA-6 Human genes 0.000 claims description 11
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims description 11
- 102100020993 Zinc finger protein ZFPM1 Human genes 0.000 claims description 11
- 102100020996 Zinc finger protein ZFPM2 Human genes 0.000 claims description 11
- 108010023082 activin A Proteins 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 10
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 10
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 102000004889 Interleukin-6 Human genes 0.000 claims description 10
- 108090000190 Thrombin Proteins 0.000 claims description 10
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 10
- 229940100601 interleukin-6 Drugs 0.000 claims description 10
- 229930002330 retinoic acid Natural products 0.000 claims description 10
- 229960001727 tretinoin Drugs 0.000 claims description 10
- LKBSMPFEKIBRGC-UHFFFAOYSA-N 2-[[2-(4-methoxyanilino)-4-pyrimidinyl]amino]ethanol Chemical compound C1=CC(OC)=CC=C1NC1=NC=CC(NCCO)=N1 LKBSMPFEKIBRGC-UHFFFAOYSA-N 0.000 claims description 9
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 9
- 238000003753 real-time PCR Methods 0.000 claims description 9
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 102100037241 Endoglin Human genes 0.000 claims description 7
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 7
- 210000001612 chondrocyte Anatomy 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 7
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 6
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 6
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 6
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 6
- 238000005138 cryopreservation Methods 0.000 claims description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 5
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 5
- 102100028892 Cardiotrophin-1 Human genes 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 5
- 108010041776 cardiotrophin 1 Proteins 0.000 claims description 5
- 230000003511 endothelial effect Effects 0.000 claims description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 5
- 239000006166 lysate Substances 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 210000003757 neuroblast Anatomy 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 238000005070 sampling Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 210000004940 nucleus Anatomy 0.000 claims description 4
- 210000000963 osteoblast Anatomy 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000003908 quality control method Methods 0.000 claims description 4
- 238000010186 staining Methods 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 3
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 3
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 3
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 claims description 3
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 claims description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 3
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 claims description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 3
- 102100028417 Fibroblast growth factor 12 Human genes 0.000 claims description 3
- 108050003239 Fibroblast growth factor 12 Proteins 0.000 claims description 3
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 claims description 3
- 108050002085 Fibroblast growth factor 20 Proteins 0.000 claims description 3
- 102100031361 Fibroblast growth factor 20 Human genes 0.000 claims description 3
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 3
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 108010024636 Glutathione Proteins 0.000 claims description 3
- 239000007995 HEPES buffer Substances 0.000 claims description 3
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 claims description 3
- 101001030243 Homo sapiens Myosin-7 Proteins 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 101000878182 Mus musculus Fibroblast growth factor 15 Proteins 0.000 claims description 3
- 102100038934 Myosin-7 Human genes 0.000 claims description 3
- 102000008730 Nestin Human genes 0.000 claims description 3
- 108010088225 Nestin Proteins 0.000 claims description 3
- 102000004067 Osteocalcin Human genes 0.000 claims description 3
- 108090000573 Osteocalcin Proteins 0.000 claims description 3
- 101150106167 SOX9 gene Proteins 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 3
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 claims description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 3
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 claims description 3
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 3
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 3
- 229960005305 adenosine Drugs 0.000 claims description 3
- 210000001789 adipocyte Anatomy 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 229940119744 dextran 40 Drugs 0.000 claims description 3
- 108090000047 fibroblast growth factor 13 Proteins 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- 238000012744 immunostaining Methods 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 229940099584 lactobionate Drugs 0.000 claims description 3
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 210000004165 myocardium Anatomy 0.000 claims description 3
- 210000005055 nestin Anatomy 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 3
- 230000005305 organ development Effects 0.000 claims description 3
- 210000004409 osteocyte Anatomy 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- 102100024210 CD166 antigen Human genes 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 241000699800 Cricetinae Species 0.000 claims description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 2
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 2
- 102100040120 Prominin-1 Human genes 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 108010071390 Serum Albumin Proteins 0.000 claims description 2
- 102000007562 Serum Albumin Human genes 0.000 claims description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 210000004381 amniotic fluid Anatomy 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 230000002175 menstrual effect Effects 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims 6
- 102000019034 Chemokines Human genes 0.000 claims 5
- 108010012236 Chemokines Proteins 0.000 claims 5
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 4
- 210000003855 cell nucleus Anatomy 0.000 claims 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 2
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims 2
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 102000004858 Growth differentiation factor-9 Human genes 0.000 claims 2
- 108090001086 Growth differentiation factor-9 Proteins 0.000 claims 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 2
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims 2
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 2
- 102100026236 Interleukin-8 Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 108010056852 Myostatin Proteins 0.000 claims 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 108010010469 Qa-SNARE Proteins Proteins 0.000 claims 2
- 102000013275 Somatomedins Human genes 0.000 claims 2
- 102000036693 Thrombopoietin Human genes 0.000 claims 2
- 108010041111 Thrombopoietin Proteins 0.000 claims 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229940053128 nerve growth factor Drugs 0.000 claims 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims 2
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 claims 1
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 claims 1
- 102000009840 Angiopoietins Human genes 0.000 claims 1
- 108010009906 Angiopoietins Proteins 0.000 claims 1
- 102400000345 Angiotensin-2 Human genes 0.000 claims 1
- 101800000733 Angiotensin-2 Proteins 0.000 claims 1
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims 1
- 108010081589 Becaplermin Proteins 0.000 claims 1
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims 1
- 108700012434 CCL3 Proteins 0.000 claims 1
- 102100025597 Caspase-4 Human genes 0.000 claims 1
- 101710090338 Caspase-4 Proteins 0.000 claims 1
- 108010075016 Ceruloplasmin Proteins 0.000 claims 1
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- 108010083698 Chemokine CCL26 Proteins 0.000 claims 1
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 1
- 102000001326 Chemokine CCL4 Human genes 0.000 claims 1
- 108010055165 Chemokine CCL4 Proteins 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 claims 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 claims 1
- 102000016917 Complement C1 Human genes 0.000 claims 1
- 108010028774 Complement C1 Proteins 0.000 claims 1
- 108010028780 Complement C3 Proteins 0.000 claims 1
- 102000016918 Complement C3 Human genes 0.000 claims 1
- 108010072220 Cyclophilin A Proteins 0.000 claims 1
- 102000012192 Cystatin C Human genes 0.000 claims 1
- 108010061642 Cystatin C Proteins 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 102100031939 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 1
- 102100020997 Fractalkine Human genes 0.000 claims 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims 1
- 108010024164 HLA-G Antigens Proteins 0.000 claims 1
- 102100025255 Haptoglobin Human genes 0.000 claims 1
- 108050005077 Haptoglobin Proteins 0.000 claims 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 claims 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 claims 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims 1
- 101100273566 Humulus lupulus CCL10 gene Proteins 0.000 claims 1
- 101150088952 IGF1 gene Proteins 0.000 claims 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108090001090 Lectins Proteins 0.000 claims 1
- 102000004856 Lectins Human genes 0.000 claims 1
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100029268 Neurotrophin-3 Human genes 0.000 claims 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 1
- 108700023477 Nucleoside diphosphate kinases Proteins 0.000 claims 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 claims 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims 1
- 102100037765 Periostin Human genes 0.000 claims 1
- 101710199268 Periostin Proteins 0.000 claims 1
- 102000011195 Profilin Human genes 0.000 claims 1
- 108050001408 Profilin Proteins 0.000 claims 1
- 239000005700 Putrescine Substances 0.000 claims 1
- 102000015799 Qa-SNARE Proteins Human genes 0.000 claims 1
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims 1
- 102100030511 Stanniocalcin-1 Human genes 0.000 claims 1
- 101710142157 Stanniocalcin-1 Proteins 0.000 claims 1
- 108010055297 Sterol Esterase Proteins 0.000 claims 1
- 102000050707 Syntaxin-11 Human genes 0.000 claims 1
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims 1
- 102400000757 Ubiquitin Human genes 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 101150109862 WNT-5A gene Proteins 0.000 claims 1
- 102000043366 Wnt-5a Human genes 0.000 claims 1
- 108700020483 Wnt-5a Proteins 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 229950006323 angiotensin ii Drugs 0.000 claims 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 230000034127 bone morphogenesis Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 244000309466 calf Species 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 210000003989 endothelium vascular Anatomy 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 229940076264 interleukin-3 Drugs 0.000 claims 1
- 229940096397 interleukin-8 Drugs 0.000 claims 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 239000002523 lectin Substances 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 230000000508 neurotrophic effect Effects 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 abstract 2
- 230000009772 tissue formation Effects 0.000 abstract 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 11
- 210000005240 left ventricle Anatomy 0.000 description 9
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000009795 derivation Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010029144 Factor IIa Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000000760 cerebral cavernous malformation Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1406—Septums, pierceable membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1412—Containers with closing means, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2009056197 | 2009-05-20 | ||
| EPPCT/EP2009/056197 | 2009-05-20 | ||
| PCT/EP2010/057004 WO2010133686A1 (en) | 2009-05-20 | 2010-05-20 | Parmaceutical composition for the treatment of heart diseases. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2011145370A RU2011145370A (ru) | 2013-06-27 |
| RU2595801C2 true RU2595801C2 (ru) | 2016-08-27 |
Family
ID=41323568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011145370/15A RU2595801C2 (ru) | 2009-05-20 | 2010-05-20 | Фармацевтическая композиция для лечения заболеваний сердца |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9446076B2 (enExample) |
| JP (1) | JP6029468B2 (enExample) |
| KR (1) | KR101689415B1 (enExample) |
| CN (2) | CN107028980A (enExample) |
| AU (1) | AU2010251151B2 (enExample) |
| BR (1) | BRPI1012116A2 (enExample) |
| CA (1) | CA2762584A1 (enExample) |
| ES (1) | ES2541212T3 (enExample) |
| IL (1) | IL216399A0 (enExample) |
| MX (1) | MX2011012183A (enExample) |
| NZ (2) | NZ623454A (enExample) |
| RU (1) | RU2595801C2 (enExample) |
| SG (1) | SG175880A1 (enExample) |
| TW (1) | TWI492707B (enExample) |
| WO (1) | WO2010133686A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8173118B2 (en) | 2004-07-30 | 2012-05-08 | Mayo Foundation For Medical Education And Research | Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin |
| US9765298B2 (en) | 2006-07-24 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Methods and materials for providing cardiac cells |
| WO2009145761A1 (en) * | 2008-05-27 | 2009-12-03 | Mayo Foundation For Medical Education And Research | Methods and materials for using cells to treat heart tissue |
| WO2011057249A2 (en) | 2009-11-09 | 2011-05-12 | The Brigham And Women's Hospital, Inc. | Treatment of heart disease |
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| WO2013007284A1 (en) * | 2011-07-08 | 2013-01-17 | Mikael Sigvardsson | A method for enriching mesenchymal stem cells and applications thereof |
| EP2833896A2 (en) * | 2012-03-30 | 2015-02-11 | University Of Southern California | Compositions and treatment methods for mesenchymal stem cell-induced immunoregulation |
| WO2013163479A1 (en) * | 2012-04-25 | 2013-10-31 | General Istrazivanja D.O.O. | Methods and compositions for treating and diagnosing acute myocardial infarction |
| US9943545B2 (en) * | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| BR112015030374A2 (pt) * | 2013-06-28 | 2017-07-25 | Otsuka Pharma Factory Inc | solução contendo trealose e dextrana para transplante de células mamíferas |
| CN103667440A (zh) * | 2013-09-05 | 2014-03-26 | 谢小冬 | Gata4基因snp位点的用途 |
| CN104922155A (zh) * | 2014-03-18 | 2015-09-23 | 中山大学孙逸仙纪念医院 | 治疗心脏疾病的细胞输送方法 |
| ES2860423T3 (es) | 2014-05-28 | 2021-10-05 | Childrens Hospital Med Ct | Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida |
| US10363278B2 (en) | 2014-06-15 | 2019-07-30 | Amnio Technology Llc | Frozen therapeutic dose and package |
| CA2963704A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
| AU2015373050B2 (en) | 2014-12-30 | 2022-09-29 | Cell Cure Neurosciences Ltd. | RPE cell populations and methods of generating same |
| WO2016141234A1 (en) | 2015-03-03 | 2016-09-09 | Regents Of The University Of Minnesota | Etv2 and uses thereof |
| US10874092B2 (en) | 2015-06-30 | 2020-12-29 | Regents Of The University Of Minnesota | Humanized skeletal muscle |
| CN108472318A (zh) * | 2015-06-30 | 2018-08-31 | 明尼苏达大学校董会 | 人源化心脏肌肉 |
| CN105079791A (zh) * | 2015-09-18 | 2015-11-25 | 郑榆坤 | 一种刺激体内内源干细胞的组合物及其应用 |
| WO2017064688A1 (en) * | 2015-10-15 | 2017-04-20 | Cells For Cells, S.P.A. | Neurite regeneration therapy based on exosomes derived from menstrual stem cells |
| US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| CN109415685B (zh) | 2016-05-05 | 2023-07-04 | 儿童医院医疗中心 | 用于体外制造胃底组织的方法和与其相关的组合物 |
| CN106619718A (zh) * | 2016-10-18 | 2017-05-10 | 广州赛莱拉干细胞科技股份有限公司 | 一种细胞制剂及其制备方法和应用 |
| CN106474456A (zh) * | 2016-10-18 | 2017-03-08 | 广州赛莱拉干细胞科技股份有限公司 | 一种细胞制剂及其制备方法和应用 |
| SG10202104575WA (en) | 2016-11-04 | 2021-06-29 | Childrens Hospital Med Ct | Liver organoid compositions and methods of making and using same |
| CN108070645A (zh) * | 2016-11-11 | 2018-05-25 | 中国科学院上海生命科学研究院 | Stx-t在预防和/或治疗贫血或其相关疾病的应用 |
| CA3045145A1 (en) | 2016-12-05 | 2018-06-14 | Children's Hospital Medical Center | Colonic organoids and methods of making and using same |
| US12281334B2 (en) | 2017-04-14 | 2025-04-22 | Children's Hospital Medical Center | Multi donor stem cell compositions and methods of making same |
| DE102017116204B4 (de) | 2017-07-18 | 2024-06-27 | Universität Rostock | Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration |
| CN109497038A (zh) * | 2017-09-14 | 2019-03-22 | 青岛瑞思德生物科技有限公司 | 一种脂肪保存液及其制备方法 |
| WO2019074793A1 (en) | 2017-10-10 | 2019-04-18 | Children's Hospital Medical Center | OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME |
| CN107648592B (zh) * | 2017-11-13 | 2021-05-14 | 深圳市喆邦生物工程有限公司 | 趋化因子ccl4作为制备治疗骨折药物的应用 |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| BR112020013238A2 (pt) | 2017-12-29 | 2020-12-01 | Cell Cure Neurosciences Ltd. | composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana |
| CN108244096B (zh) * | 2018-01-10 | 2019-01-04 | 暨赛再生医学科技有限公司 | 一种长期保存过表达vegf的血管内皮祖细胞的保存液 |
| CN108379662A (zh) * | 2018-02-08 | 2018-08-10 | 深圳大图科创技术开发有限公司 | 一种干细胞在心脏移植模型的应用 |
| CN108546757B (zh) * | 2018-03-05 | 2021-09-07 | 上海长海医院 | Zfpm2-as1在制备胃癌诊断试剂或试剂盒中的应用 |
| CA3106634A1 (en) | 2018-07-26 | 2020-01-30 | Children's Hospital Medical Center | Hepato-biliary-pancreatic tissues and methods of making same |
| CN110812369A (zh) * | 2018-08-10 | 2020-02-21 | 浙江楚沅生物科技有限公司 | 用于治疗组织坏死或改善心脏功能的药物 |
| CN112823012A (zh) | 2018-09-12 | 2021-05-18 | 儿童医院医学中心 | 用于产生造血干细胞及其衍生物的类器官组合物 |
| CN109266604B (zh) * | 2018-10-10 | 2020-11-10 | 浙江神雁精准医疗科技有限公司 | 包含干细胞活性物质的组合物及其制备方法 |
| WO2020160371A1 (en) | 2019-02-01 | 2020-08-06 | The University Of Hong Kong | Innervated organoid compositions and methods of making same |
| CN109769799A (zh) * | 2019-03-20 | 2019-05-21 | 江苏瑞思坦生物科技有限公司 | 一种人脂肪组织保存液及其制备方法 |
| CN111939245B (zh) * | 2019-05-16 | 2024-03-01 | 龚笑海 | 一种心脏治疗和保护的药物组合物 |
| CA3141807A1 (en) | 2019-05-31 | 2020-12-03 | Children's Hospital Medical Center | Methods of generating and expanding hematopoietic stem cells |
| US12534709B2 (en) | 2019-05-31 | 2026-01-27 | Children's Hospital Medical Center | Shaped organoid compositions and methods of making same |
| EP4015623A1 (en) * | 2020-12-17 | 2022-06-22 | Universite De Montpellier | Pre-treatment of msc with ppar beta/delta agonist for treatment of ischemia-reperfusion injury |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006015127A2 (en) * | 2004-07-30 | 2006-02-09 | Mayo Foundation For Medical Education And Research | Treating cardiovascular tissue |
| WO2006080434A1 (ja) * | 2005-01-27 | 2006-08-03 | Japan Health Sciences Foundation | 間葉系幹細胞を含む細胞シート |
| WO2008109839A1 (en) * | 2007-03-07 | 2008-09-12 | Mayo Foundation For Medical Education And Research | Cardiac-specific progenitor cells |
| WO2008147057A1 (en) * | 2007-05-25 | 2008-12-04 | Rnl Bio Co., Ltd | Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6045990A (en) * | 1998-07-09 | 2000-04-04 | Baust; John M. | Inclusion of apoptotic regulators in solutions for cell storage at low temperature |
| US6632666B2 (en) * | 2000-01-14 | 2003-10-14 | Biolife Solutions, Inc. | Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media |
| US20040071665A1 (en) | 2000-09-05 | 2004-04-15 | Yong-Fu Xiao | Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal |
| US6921633B2 (en) * | 2002-11-18 | 2005-07-26 | Biolife Solutions Incorporated | Methods and compositions for the preservation of cells, tissues or organs in the vitreous state |
| KR100674783B1 (ko) * | 2003-12-09 | 2007-01-25 | (주)안트로젠 | 세포 이식을 위한 세포의 생산 방법 |
| CA2603857A1 (en) * | 2005-03-31 | 2006-11-16 | Mytogen, Inc. | Treatment for heart disease |
| US8074465B2 (en) * | 2005-09-12 | 2011-12-13 | Genzyme Corporation | Thermally insulated transport container for cell-based products and related methods |
| US9765298B2 (en) * | 2006-07-24 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Methods and materials for providing cardiac cells |
| AU2008204541B2 (en) | 2007-01-09 | 2014-07-10 | Lead Pharma Cel Models Ip B.V. | Provision of new cardiomyocyte progenitor cells and cardiomyocytes derived therefrom |
| FR2917381B1 (fr) | 2007-06-15 | 2009-10-16 | Ceva Sante Animale Sa | Conditionnement plastique multicouche pour la conservation d'une composition pharmaceutique |
| KR101995016B1 (ko) * | 2007-12-04 | 2019-06-28 | 프로테오바이오엑티브스 피티와이 엘티디 | 전구 세포의 보호 및 그의 분화 조절 |
| EP2100954A1 (en) * | 2008-03-10 | 2009-09-16 | Assistance Publique - Hopitaux de Paris | Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications |
| WO2009121002A1 (en) * | 2008-03-27 | 2009-10-01 | Biolife Solutions, Inc. | Materials and methods for hypothermic collection of whole blood |
| WO2009145761A1 (en) | 2008-05-27 | 2009-12-03 | Mayo Foundation For Medical Education And Research | Methods and materials for using cells to treat heart tissue |
| BE1018733A3 (fr) | 2009-04-29 | 2011-07-05 | Cardio3 Biosciences Sa | Dispositif pour la delivrance d'un agent therapeutique. |
-
2010
- 2010-05-20 US US13/321,224 patent/US9446076B2/en not_active Expired - Fee Related
- 2010-05-20 MX MX2011012183A patent/MX2011012183A/es active IP Right Grant
- 2010-05-20 AU AU2010251151A patent/AU2010251151B2/en not_active Ceased
- 2010-05-20 RU RU2011145370/15A patent/RU2595801C2/ru not_active IP Right Cessation
- 2010-05-20 KR KR1020117028912A patent/KR101689415B1/ko not_active Expired - Fee Related
- 2010-05-20 CN CN201610828324.3A patent/CN107028980A/zh active Pending
- 2010-05-20 NZ NZ623454A patent/NZ623454A/en not_active IP Right Cessation
- 2010-05-20 WO PCT/EP2010/057004 patent/WO2010133686A1/en not_active Ceased
- 2010-05-20 TW TW099116052A patent/TWI492707B/zh not_active IP Right Cessation
- 2010-05-20 ES ES10723556.6T patent/ES2541212T3/es active Active
- 2010-05-20 SG SG2011081072A patent/SG175880A1/en unknown
- 2010-05-20 NZ NZ596162A patent/NZ596162A/en not_active IP Right Cessation
- 2010-05-20 BR BRPI1012116A patent/BRPI1012116A2/pt not_active Application Discontinuation
- 2010-05-20 CN CN2010800211106A patent/CN102438636A/zh active Pending
- 2010-05-20 JP JP2012511301A patent/JP6029468B2/ja not_active Expired - Fee Related
- 2010-05-20 CA CA2762584A patent/CA2762584A1/en not_active Abandoned
-
2011
- 2011-11-16 IL IL216399A patent/IL216399A0/en not_active IP Right Cessation
-
2016
- 2016-03-04 US US15/061,182 patent/US10086016B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006015127A2 (en) * | 2004-07-30 | 2006-02-09 | Mayo Foundation For Medical Education And Research | Treating cardiovascular tissue |
| WO2006080434A1 (ja) * | 2005-01-27 | 2006-08-03 | Japan Health Sciences Foundation | 間葉系幹細胞を含む細胞シート |
| WO2008109839A1 (en) * | 2007-03-07 | 2008-09-12 | Mayo Foundation For Medical Education And Research | Cardiac-specific progenitor cells |
| WO2008147057A1 (en) * | 2007-05-25 | 2008-12-04 | Rnl Bio Co., Ltd | Composition for treating ischemic limb disease comprising stem cells derived from adipose tissue |
Also Published As
| Publication number | Publication date |
|---|---|
| IL216399A0 (en) | 2012-01-31 |
| NZ623454A (en) | 2015-12-24 |
| AU2010251151B2 (en) | 2015-08-20 |
| SG175880A1 (en) | 2011-12-29 |
| CN102438636A (zh) | 2012-05-02 |
| JP6029468B2 (ja) | 2016-11-24 |
| KR101689415B1 (ko) | 2016-12-23 |
| TWI492707B (zh) | 2015-07-21 |
| JP2012527432A (ja) | 2012-11-08 |
| WO2010133686A8 (en) | 2012-03-08 |
| CN107028980A (zh) | 2017-08-11 |
| US20160279168A1 (en) | 2016-09-29 |
| ES2541212T3 (es) | 2015-07-16 |
| MX2011012183A (es) | 2012-03-06 |
| WO2010133686A1 (en) | 2010-11-25 |
| TW201108935A (en) | 2011-03-16 |
| AU2010251151A1 (en) | 2011-11-24 |
| US9446076B2 (en) | 2016-09-20 |
| RU2011145370A (ru) | 2013-06-27 |
| US10086016B2 (en) | 2018-10-02 |
| BRPI1012116A2 (pt) | 2016-03-15 |
| KR20120046107A (ko) | 2012-05-09 |
| NZ596162A (en) | 2014-06-27 |
| CA2762584A1 (en) | 2010-11-25 |
| HK1163500A1 (en) | 2012-09-14 |
| US20120128638A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6029468B2 (ja) | 心臓病治療用医薬組成物 | |
| RU2372924C2 (ru) | Применение композиции, состоящей из концентрированной клеточной популяции, представляющей собой стволовые клетки и недифференцированные клетки-предшественники | |
| KR101614823B1 (ko) | 조직 복구 및 재생을 위한 세포 증식 방법 및 약제학적 제제 | |
| JP6405304B2 (ja) | 脂肪由来幹細胞作製システムおよび方法 | |
| EP2331679B1 (en) | Ischemic tissue cell therapy | |
| JP2012527432A5 (enExample) | ||
| EP2076588B1 (en) | Expansion method for adult stem cells from blood, particularly peripheral blood, and relative application in medical field | |
| TW201130977A (en) | Mesenchymal stem cells (MSCs) isolated from mobilized peripheral blood | |
| CN111542350A (zh) | 用于制备脂肪来源干细胞的系统和方法 | |
| CN114874982A (zh) | 一种增强脐带间充质干细胞分泌血管内皮生长因子的培养方法 | |
| CN120608017A (zh) | 一种诱导或改善间充质干细胞的创伤愈合性质的方法 | |
| US20160158292A1 (en) | Method and apparatus for recovery of umbilical cord tissue derived regenerative cells and uses thereof | |
| EP2432482B1 (en) | Pharmaceutical composition for the treatment of heart diseases. | |
| CN106606512B (zh) | 一种用于治疗心肌梗死的混合细胞制剂及制备方法与应用 | |
| Fujiwara et al. | Effect of platelet lysate on Schwann-like cell differentiation of equine bone marrow-derived mesenchymal stem cells | |
| CN106659560A (zh) | 生殖腺来源的侧群干细胞 | |
| HK1163500B (en) | Pharmaceutical composition for the treatment of heart diseases | |
| US20200325443A1 (en) | Method of inducing or improving wound healing properties of mesenchymal stem cells | |
| Wiest et al. | Optimizing extracellular vesicle yield for clinical application | |
| KR101228625B1 (ko) | 인간 유래 단핵구 세포의 활성화 배지, 및 활성화된 단핵구 세포 | |
| KR20230087559A (ko) | 정상 핵형을 갖는 신규한 nr1 es-유래 신경 줄기세포 및 이의 용도 | |
| HK1162051A (en) | Ischemic tissue cell therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180521 |